Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the cheap hot stocks to invest in right now. On January 30, Barclays analyst Glen Santangelo raised the price target for Teva Pharmaceuticals to $38 from $35 with an Overweight rating. Following Teva Pharmaceuticals’ Q4 2025 report, the firm updated its financial model and expressed continued confidence in the stock’s current valuation.

A day before that, Scotiabank raised the price target on Teva Pharmaceuticals to $40 from $35 while maintaining an Outperform rating. The firm is positive on the stock following Q4 2025 results and noted that the company’s execution continues to exceed expectations.

In other news, on January 14, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced that the New England Journal of Medicine published Phase 3 data from the SPACE trial, confirming that AJOVY (fremanezumab-vfrm) significantly reduces monthly migraine and headache days in children and adolescents (ages 6–17). Following its August 2025 FDA approval for pediatric patients weighing 45 kg or more, AJOVY is now the first and only CGRP antagonist available for both adults and children.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic and other medicines & biopharmaceutical products in the US, Europe, Israel, and internationally.

While we acknowledge the potential of TEVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.